Colorectal Cancer News and Research

Latest Colorectal Cancer News and Research

Lifestyle changes and screening tools prove to reduce cancer risk, says doctor

President Nixon funded research to wage a war on cancer, a long battle that we're still fighting today. While the last 40 years haven't brought us a cure, we have made some meaningful progress in developing tools and knowledge to take a bite out of our cancer risk.

10 Jan 2014

Biothera reports positive results from Phase 2 clinical trial of Imprime PGG in NSCLC patients

Biothera today reported positive results from its proof of concept Phase 2 clinical trial in 90 patients with advanced non-small cell lung cancer (NSCLC) at the American Association for Cancer Research and the International Association for the Study of Lung Cancer joint conference on the Molecular Origins of Lung Cancer in San Diego.

8 Jan 2014

Navidea Biopharmaceuticals, GMST sign distribution agreement for Lymphoseek Injection in Taiwan

Navidea Biopharmaceuticals, Inc., a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, announced today it has entered into a distribution agreement for Lymphoseek (technetium Tc 99m tilmanocept) Injection in Taiwan with Global Medical Solutions Taiwan, Ltd., a leading in-country distributor of nuclear medicine and diagnostic imaging products.

7 Jan 2014

Researchers develop new tool that accurately predicts individual's risk of colorectal cancer

Researchers at Cleveland Clinic have developed a new tool called CRC-PRO that allows physicians to quickly and accurately predict an individual's risk of colorectal cancer, as published in the current edition of the Journal of the American Board of Family Medicine.

5 Jan 2014

European Commission approves update of Erbitux to treat patients with RAS wild-type mCRC

Merck Serono, the biopharmaceutical division of Merck, today announced that the European Commission has approved the Type II variation to amend the Erbitux(cetuximab) product information, updating the indication for Erbitux to the treatment of patients with RAS wild-type metastatic colorectal cancer (mCRC).

23 Dec 2013

Study finds milk serves as protective carrier of bioactive molecules

Polyphenols found in tea manifest anti-cancer effects but their use is limited by poor bioavailability and disagreeable taste. A new study in the Journal of Dairy Science- finds that when epigallocatechin gallate (EGCG), the major extractable polyphenol in green tea and the most biologically active, when diluted in skim milk or other milk complexes remains bioactive and continues to reduce colon cancer cell proliferation in culture at concentrations higher than 0.03 mg of EGCG/mL.

20 Dec 2013

Patient assessment of clinical services quality predicts survival for colorectal cancer patients

Patient assessment of clinical services quality was shown to be an independent predictor of survival for colorectal cancer patients in a study recently published in the Journal of Healthcare Quality, the peer reviewed publication of the National Association for Healthcare Quality (NAHQ), www.nahq.org.

20 Dec 2013

Sanofi and Regeneron Pharmaceuticals team up with ACC to enhance clinical research with alirocumab

Sanofi and Regeneron Pharmaceuticals, Inc. today announced an innovative collaboration with the American College of Cardiology focused on enhancing clinical research with alirocumab, an investigational monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9). PCSK9 is known to contribute to circulating low-density lipoprotein cholesterol (LDL-C) levels. Alirocumab is being co-developed by Sanofi and Regeneron.

19 Dec 2013

FDA accepts Regeneron's EYLEA Injection sBLA for standard review

Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has accepted for standard review the Company's supplemental Biologics License Application for EYLEA (aflibercept) Injection for the treatment of Diabetic Macular Edema.

18 Dec 2013

Genetically targeted drugs used for lung cancer may also have applications in colorectal cancer patients

A University of Colorado Cancer Center study published online ahead of print in the journal Molecular Cancer Research shows that ALK and ROS1 gene rearrangements known to drive subsets of lung cancer are also present in some colorectal cancers. These results imply that drugs used to target ALK and ROS1 in lung cancer may also have applications in this subset of colorectal cancer patients.

17 Dec 2013

Navidea seeks FDA approval for marketing Lymphoseek Injection for SLN detection

Navidea Biopharmaceuticals, Inc., a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, announced today that it has submitted a Supplemental New Drug Application with the U.S. Food and Drug Administration seeking approval for the marketing and sale of Lymphoseek (technetium 99m tilmanocept) Injection for sentinel lymph node detection in patients with head and neck cancer, an indication for which Lymphoseek was also granted Fast Track designation earlier this month.

17 Dec 2013

New report shows death rates for lung cancer dropping at a faster pace

The Annual Report to the Nation on the Status of Cancer, covering the period 1975, showed death rates for lung cancer, which accounts for more than one in four cancer deaths, dropping at a faster pace than in previous years. The recent larger drop in lung cancer deaths is likely the result of decreased cigarette smoking prevalence over many years, and is now being reflected in mortality trends. The lung cancer death rate decline, as well as declines in colorectal, breast, and prostate cancer death rates, has also helped drive decreases in death rates for all cancers types combined, a trend that began about 20 years ago.

17 Dec 2013

Low vitamin D a consequence not a cause of ill health

Low vitamin D status is a marker of ill health rather than an underlying cause of disease, say the authors of a systematic review published in The Lancet Diabetes and Endocrinology.

16 Dec 2013

Study shows effectiveness of PAM50-based Prosigna Breast Cancer Prognostic Gene Signature Assay

NanoString Technologies, Inc., a provider of life science tools for translational research and molecular diagnostic products, today announced new results from a combined analysis of the Austrian Breast & Colorectal Cancer Study Group 8 (ABCSG-8) and Trans-Arimidex, Tamoxifen, Alone or in Combination (TransATAC) studies. These results, which evaluated samples from 2,137 patients, suggest that the PAM50-based Prosignaz Breast Cancer Prognostic Gene Signature Assay may help identify women with late distant recurrence after five years of endocrine treatment.

13 Dec 2013

AVEO announces data from planned interim analysis of Phase 2 BATON study in CRC patients

AVEO Oncology today announced that data from a planned interim analysis of the Phase 2 BATON (Biomarker Assessment of Tivozanib in ONcology) study in patients with colorectal cancer (CRC) indicate that the study is unlikely to meet the primary endpoint in the intent-to-treat patient population.

13 Dec 2013

Circulating nucleosomes and colorectal cancer diagnostics: an interview with Dr. Stefan Holdenrieder, University Hospital Bonn

For my MD thesis I modified and evaluated an immunological assay that detected the cell death products “nucleosomes” as a new blood-based cancer biomarker. As cell death processes are enhanced or suppressed during different stages of tumor development, it was assumed that they may enable stage-dependent detection of cancer disease.

12 Dec 2013

Queen's University to lead €6 million European study to find new treatments for bowel cancer

Queen's University has announced it is to lead a -6 million European study to find new treatments for bowel cancer.

12 Dec 2013

Report: Screen all endometrial cancer patients for Lynch syndrome

A recent article by Norris Cotton Cancer Center researchers published in the January 2014 issue of the journal Clinical Chemistry reviews the scientific evidence that warrants screening all endometrial cancers for Lynch syndrome. Next to colorectal cancer, endometrial cancer is the most common form of cancer in women with Lynch syndrome.

12 Dec 2013

Queen's University heads key European study to find new treatments for bowel cancer

Queen's University has announced it is to lead a €6 million European study to find new treatments for bowel cancer.

11 Dec 2013

Navidea receives Fast Track designation for Lymphoseek injection

Navidea Biopharmaceuticals, Inc. (NYSE MKT:NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, announced today that the US Food and Drug Administration (FDA) has granted Fast Track designation to Lymphoseek® (technetium 99m tilmanocept) Injection for sentinel lymph node detection in patients with head and neck cancer.

11 Dec 2013

Colorectal Cancer News and Research

Latest Colorectal Cancer News and Research

Lifestyle changes and screening tools prove to reduce cancer risk, says doctor

Biothera reports positive results from Phase 2 clinical trial of Imprime PGG in NSCLC patients

Navidea Biopharmaceuticals, GMST sign distribution agreement for Lymphoseek Injection in Taiwan

Researchers develop new tool that accurately predicts individual's risk of colorectal cancer

European Commission approves update of Erbitux to treat patients with RAS wild-type mCRC

Study finds milk serves as protective carrier of bioactive molecules

Patient assessment of clinical services quality predicts survival for colorectal cancer patients

Sanofi and Regeneron Pharmaceuticals team up with ACC to enhance clinical research with alirocumab

FDA accepts Regeneron's EYLEA Injection sBLA for standard review

Genetically targeted drugs used for lung cancer may also have applications in colorectal cancer patients

Navidea seeks FDA approval for marketing Lymphoseek Injection for SLN detection

New report shows death rates for lung cancer dropping at a faster pace

Low vitamin D a consequence not a cause of ill health

Study shows effectiveness of PAM50-based Prosigna Breast Cancer Prognostic Gene Signature Assay

AVEO announces data from planned interim analysis of Phase 2 BATON study in CRC patients

Circulating nucleosomes and colorectal cancer diagnostics: an interview with Dr. Stefan Holdenrieder, University Hospital Bonn

Queen's University to lead €6 million European study to find new treatments for bowel cancer

Report: Screen all endometrial cancer patients for Lynch syndrome

Queen's University heads key European study to find new treatments for bowel cancer

Navidea receives Fast Track designation for Lymphoseek injection

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Shaping the future of lab automation through AI and robotics

Colorectal Cancer News and Research

Latest Colorectal Cancer News and Research

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Shaping the future of lab automation through AI and robotics

Newsletters you may be interested in